Eosinophilia as a predictor of response to checkpoint inhibition in patients with metastatic melanoma.

Eosinophilia as a predictor of response to checkpoint inhibition in patients with metastatic melanoma.

Blog Article

Immune checkpoint inhibitors can prolong survival and lead to cure in metastatic melanoma.Baseline bondage-kits indices have not proven clinically useful as predictors of response.Identifying early treatment response would have clinical and economic benefits.The Christchurch Hospital Oncology Department maintains a prospective registry of melanoma patients treated with pembrolizumab and nivolumab.

Patients were classified as either alive-and-progression-free (responders) or as dead-or-progressive-disease (non-responders).Thirty-six patients were included.Median follow-up was 16 months (range 1-41 months).Twelve patients died and 3 had progressive disease.

Mean eosinophils were 0.168x109/L in responders and 0.198x109/L in non-responders (p=0.565).

In responders, eosinophil count significantly increased after three treatments to 0.37x109/L (p=0.009).There Pentair SunTouch was a significant difference in the change in eosinophil count between responders and non-responders, p=0.

02.In this small study, response to immune checkpoint inhibitors was associated with increased eosinophils.This finding may help predict subsequent clinical response and may help in assessment of suspected pseudo-progression.